Trials / Completed
CompletedNCT06623955
Maternal Serum Stathmin-1 Levels in Preeclampsia
A Comparative Study of Maternal Serum Stathmin-1 Levels in Pregnancies With Preeclampsia, Severe Preeclampsia, and Healthy Controls
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 84 (actual)
- Sponsor
- Başakşehir Çam & Sakura City Hospital · Other Government
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This study investigates maternal serum Stathmin-1 (STMN-1) levels in pregnancies complicated by preeclampsia and severe preeclampsia, compared to healthy pregnancies. The aim is to explore potential differences in STMN-1 levels among these groups to better understand its role in preeclampsia pathophysiology. Maternal serum STMN-1 levels will be measured between 32-34 weeks of gestation, and patients will be monitored until delivery to assess whether they develop preeclampsia or severe preeclampsia.
Conditions
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2024-01-01
- Completion
- 2024-03-01
- First posted
- 2024-10-02
- Last updated
- 2024-10-02
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT06623955. Inclusion in this directory is not an endorsement.